NASDAQ:TCRX TScan Therapeutics (TCRX) Stock Price, News & Analysis $0.77 +0.03 (+3.69%) As of 11:46 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About TScan Therapeutics Stock (NASDAQ:TCRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TScan Therapeutics alerts:Sign Up Key Stats Today's Range$0.74▼$0.7850-Day Range$0.74▼$1.2652-Week Range$0.73▼$2.57Volume216,202 shsAverage Volume724,218 shsMarket Capitalization$50.25 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingHold Company Overview TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins. The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors. TScan has established strategic collaborations with major pharmaceutical partners to advance its lead candidates through clinical development. These partnerships enable the company to combine its TCR discovery capabilities with the resources and expertise of established drug developers, while retaining the ability to progress additional assets independently. Founded in 2018 and headquartered in Cambridge, Massachusetts, TScan Therapeutics went public in late 2021. Under the leadership of Chief Executive Officer Kenneth Song, the company employs a multidisciplinary team of immunologists, molecular biologists and data scientists. While its core operations are based in the United States, TScan’s research partnerships and clinical trial activities extend globally, reflecting its ambition to deliver novel T-cell therapies to patients around the world.AI Generated. May Contain Errors. Read More TScan Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreTCRX MarketRank™: TScan Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 331st out of 832 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingTScan Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialTScan Therapeutics has a consensus price target of $6.00, representing about 694.7% upside from its current price of $0.76.Amount of Analyst CoverageTScan Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about TScan Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for TScan Therapeutics are expected to grow in the coming year, from ($1.11) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TScan Therapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TScan Therapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTScan Therapeutics has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about TScan Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.26% of the float of TScan Therapeutics has been sold short.Short Interest Ratio / Days to CoverTScan Therapeutics has a short interest ratio ("days to cover") of 1.19, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TScan Therapeutics has recently increased by 95.50%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTScan Therapeutics does not currently pay a dividend.Dividend GrowthTScan Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.29 News SentimentTScan Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for TScan Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for TCRX on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TScan Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.25% of the stock of TScan Therapeutics is held by insiders.Percentage Held by Institutions82.83% of the stock of TScan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TScan Therapeutics' insider trading history. Receive TCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TCRX Stock News HeadlinesTScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme MalignanciesJuly 29 at 7:00 AM | globenewswire.comCritical Comparison: Seres Therapeutics (NASDAQ:MCRB) versus TScan Therapeutics (NASDAQ:TCRX)July 20, 2026 | americanbankingnews.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.July 30 at 1:00 AM | Altimetry (Ad)TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by BrokeragesJuly 19, 2026 | americanbankingnews.comTScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceJune 24, 2026 | globenewswire.comTScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic ...June 23, 2026 | markets.businessinsider.comTScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell TransplantationJune 22, 2026 | globenewswire.comCellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic MalignanciesJune 3, 2026 | businesswire.comSee More Headlines TCRX Stock Analysis - Frequently Asked Questions How have TCRX shares performed this year? TScan Therapeutics' stock was trading at $1.00 on January 1st, 2026. Since then, TCRX shares have decreased by 24.5% and is now trading at $0.7550. How were TScan Therapeutics' earnings last quarter? TScan Therapeutics, Inc. (NASDAQ:TCRX) posted its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.22). The firm earned $0.98 million during the quarter, compared to analysts' expectations of $2.50 million. TScan Therapeutics had a negative trailing twelve-month return on equity of 91.94% and a negative net margin of 1,360.61%. When did TScan Therapeutics IPO? TScan Therapeutics (TCRX) raised $107 million in an initial public offering on Thursday, July 15th 2021. The company issued 6,666,667 shares at $15.00-$17.00 per share. How do I buy shares of TScan Therapeutics? Shares of TCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TScan Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that TScan Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings5/06/2026Today7/30/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TCRX CIK1783328 Webwww.tscan.com Phone857-399-9500FaxN/AEmployees100Year Founded2018Price Target and Rating Average Price Target for TScan Therapeutics$6.00 High Price Target$7.00 Low Price Target$5.00 Potential Upside/Downside+694.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$129.77 million Net Margins-1,360.61% Pretax Margin-1,360.61% Return on Equity-91.94% Return on Assets-50.15% Debt Debt-to-Equity Ratio0.34 Current Ratio6.65 Quick Ratio6.65 Sales & Book Value Annual Sales$10.32 million Price / Sales4.78 Cash FlowN/A Price / Cash FlowN/A Book Value$2.16 per share Price / Book0.35Miscellaneous Outstanding Shares65,350,000Free Float61,267,000Market Cap$49.34 million OptionableNot Optionable Beta1.04 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:TCRX) was last updated on 7/30/2026 by MarketBeat.com Staff. From Our PartnersThis Quiet Metals Story Is Starting To Stack UpA small North American mining company just hit 57-for-57 on exploration drilling—and that's only part of the s...i2i Marketing Group, LLC | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredPass by August 7… or wait until 2027?Right now, your phone is recording exactly where you are. It does this roughly every two minutes. Precise coor...Crypto 101 Media | SponsoredA $5 stock inside Kennedy Space Center?A small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...Freedom Financial | SponsoredSpaceX just minted 4,400 millionairesSpaceX's $1.75 trillion IPO turned more than 4400 employees into millionaires, according to The New York Times...The Oxford Club | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TCRX Stock Alerts